(NASDAQ: DSGN) Design Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.98%.
Design Therapeutics's earnings in 2025 is -$47,779,000.On average, 2 Wall Street analysts forecast DSGN's earnings for 2025 to be -$65,963,508, with the lowest DSGN earnings forecast at -$73,041,138, and the highest DSGN earnings forecast at -$58,885,878. On average, 2 Wall Street analysts forecast DSGN's earnings for 2026 to be -$74,739,769, with the lowest DSGN earnings forecast at -$80,968,083, and the highest DSGN earnings forecast at -$68,511,455.
In 2027, DSGN is forecast to generate -$86,063,976 in earnings, with the lowest earnings forecast at -$86,063,976 and the highest earnings forecast at -$86,063,976.